Matthew A. Warner-Blankenship
Matt is a shareholder of the Davis Brown Law Firm. He joined the Business Division as a patent lawyer in August 2011 with a practice that focuses on intellectual property. Matt is a registered patent attorney, able to practice in front of the United States Patent and Trademark Office.
Matt provides advice and serves as counsel to a diverse group of clients ranging from small entrepreneurial start-ups to large academic institutions and corporate entities. Matt’s work for these clients includes managing intellectual property portfolios and drafting and prosecuting patent applications. Matt’s academic scientific background is invaluable to his clients in the medical and biotech industries.
- CSU Ventures
- Living Ink Technologies
- Mid-American Energy
- Miret Surgical Inc.
- NuTechVentures, Inc.
- Stanford University, Office of Technology Licensing
- Tasso, Inc.
- Titan Tire
- Tulane University
- University of California, San Francisco
- University of Iowa Research Foundation
- University of South Dakota
- Virtual Incision Corporation
Publications, Speeches and Seminars
- NDAs, Non-Competes & IP: The Basics & Protecting Yourself, Grinnell College, December 2015.
- The Basics of Protecting Intellectual Property Assets, Valley High School, January 2015
- Trademarks & IP Practice, Drake University, November 2014
- Trademarks & IP Practice, Drake University, October 2013
- Right of Publicity Laws: Iowa, Practical Law Company, October 2013
- Trademark Laws: Iowa, Practical Law Company, October 2013
- Patent Trolls: Keeping Them Under the Bridge, Association of Corporate Counsel, Iowa Chapter, October 2012
- Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. (February 2009).
- Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. Bhattacharyya S, Chen SJ, Wu M, Warner-Blankenship M, Ning H, Lakos G,
Mori Y, Chang E, Nihijima C, Takehara K, Feghali-Bostwick C, Varga J. (October 2008)
- Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-beta responsiveness. Mori Y, Hinchcliff M, Wu M, Warner-Blankenship M, M Lyons K, Varga J (March 2008).